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1. Introduction 
Vasculitis is the inflammation of a blood or lymph vessel (Merriam – Webster Online 
Dictionary, 2011). Vasculitis is a broad term used to include a group of syndromes 
characterized by inflammation, fibrinoid necrosis or formation of granulomas in the blood 
vessel walls. These can be localized or multifocal, and have different causes and 
manifestations, depending on the location, size, presence or absence of necrosis. The latter 
can affect different organs. The vasculitides can be classified as primary or secondary, and 
are usually a diagnostic challenge for the physician. An open mind and great deal of 
suspicion is required. Once vasculitis is suspected, a thorough and systematic approach is 
mandatory. Laboratory tests, imaging studies, and, on occasion, tissue biopsies will help 
achieve an accurate diagnosis. Its etiology is also diverse (González-Gay et al., 2005) and 
hence provides the patient with an efficient and appropriate treatment. 
Recent advances in technology, with more complete serologic, histochemical, and detailed 
images, have helped in understanding and differentiating vasculitis from each other. This 
has resulted in a classification based on etiology, as well as the identification of possible 
prevention techniques, and strategic treatments. 
Medications can induce different side effects, including vasculitis. There are two recognized 
presentations: Drug Induced Lupus (DIL), and Drug Induced Vasculitis (DIV). These are 
difficult to separate, and are usually superimposed. Among the latter, one of the most well 
recognized is Antineutrophil cytoplasmic antibody (ANCA) associated autoimmune disease 
induced by antithyroid drugs (Aloush V et al., 2006; Bonaci-Nikolic B et al, 2005; Wiik, 2005; 
Pillinger & Staud, 2006). It has been proposed that neutrophile myloperoxidase (MPO) 
reacts with propylthiouracil (PTU), transforming this in a sulfa form, which initiates a chain 
reaction with activation of T lymphocytes, and B lymphocytes that induces vascular 
inflammation (Aloush V et al., 2006, Pillinger & Staud, 2006). It is interesting to note that, 
despite the elimination of PTU, the patient may continue having ANCA, and relapses of the 
www.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 
 
288 
disease (Bonaci-Nikolic B et al., 2005, Aloush V et al., 2006, Bonaci-Nikolic B et al., 2005, 
Pillinger & Staud, 2006, Choi HK et al., 2000). 
This article will focus on the historic evolution of the recognition of vasculitides as an 
autoimmune entity. We will also describe its pathophysiology, clinical presentation and 
treatment; paying special attention to drug induced vasculitides. Medications can induce 
different reactions, from local to systemic ones, including vasculitis. The skin and 
subcutaneous tissue are common targets, producing rashes and skin discolorations, usually 
associated with pruritus, edema, and, on occasion, ulceration and necrosis. There might be 
concomitant arthralgias and myalgias. In these cases, the discontinuation of the medication 
is recommended, and immunosuppressive therapies are usually required. 
2. Epidemiology of small vessel vasculitis  
Vasculitides are rare entities, and trustable epidemiologic data is limited. An annual 
incidence of cutaneous forms in 38.6 cases per million people has been estimated. It is 
usually most common in women (50.4 cases per million), than in men (26 cases per million). 
In any case, these are approximations, and likely underestimated, because some of the 
presentations like leucopenia are considered separately (Watts RA et al., 1998, Watts RA et 
al., 2000, Tidman, M et al., 1998). 
The first publications regarding drug induced vasculitis described reactions by sulfadiazine 
and hydralazine, and referred to a DIL (Hofman BJ, 1945; Alarcon D, 1967; Scott DGI, 2000). 
In 1953 it was demonstrated that 7% of patients that took hydralazine for the treatment of 
hypertension develop DIL. These patients present fever, arthralgias, arthritis, myalgias, and 
serositis involving the pleura and pericardium. It is more common after prolonged use and 
in patients with advanced age. Antinuclear antibodies (ANA) are usually positive with a 
homogenous pattern, and autoantibodies to the nucleosome subunit (H2AH2B)-DNA. These 
patients rarely develop double stranded DNA antibodies (anti-DNA), which usually happen 
in DIL by sulphasalazine. The latter patients are usually carriers of HLA DR 0301, which is a 
recognized predisposing factor for DIL (Bonaci-Nikolic B et al., 2005, Morrow JD et al., 1953, 
Yung & Richardson 1994). 
There are different ANA that are responsible for DIL (Yung &Richardson, 1994; Burlingame 
& Rubin, 1996; Ayer LM, 1994). These can be directed against MPO, human leukocyte 
elastase (HLE), catepsin G, lactoferrin and azurocidine, but they all have in common that 
they affect the neutrophils and monocytes in the perinuclear area (Jennette JC, 2000).  
Medications that cause DIL, may also induce DIV, and in both cases there might be 
compromise of small vessels, the skin, synovial tissues, kidneys and lungs. These further 
complicates the differentiation between the two (Aloush V et al., 2006, Bonaci-Nikolic B et 
al., 2005, ,Pillinger & Staud, 2006, Choi HK et al, 2000). 
There are two major antigens for the ANCA: MPO and proteinase (PR3) (Zhao MH, 1995). 
The combination of PR3-ANCA with normal neutrophils fixed with acetone produces a 
typical cytoplasmic discoloration, and hence the term C-ANCA. The MPO-ANCA induces a 
perinuclear change known as P-ANCA (Westman K, et al, 2003). 
Other drugs that cause DIL and DIV include, but are not limited to: carbamazepine, 
chlorpromazine, isoniazide, methimazole, alpha methyldopa, mynocicline, phenytoin, 
procainamide and quinidine (Ullman S. et al, 2004). Similar findings have been described 
with Etanercept. 
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ANCA are found also in other conditions, where its role it is not well understood (DeBant et 
al, 2005), for example: Ulcerative Colitis, Crohn’s disease and HIV (Doyle & Cuellar, 2003; 
Mekel PA, 2001). 
3. Historical evolution  
The first descriptions were made by Claudio Galeno, when he concluded that some of the 
peripheral arterial aneurysms that he found were of iatrogenic nature (Litton & Resurh, 
1978). These are well written is his book “De tumoribus pareter naturam”. Later, in the XVI 
century Montpellier described vasculitis of infectious origin, specifically related to syphilis 
(Saporta A, 1624, Cited by Garrison & Morton, 1970). But it was only until the XIX century 
that vasculitis was recognized as a separate entity (Iglesias et al, 2002). In 1801, William 
Heberden started describing a vascular purpura (Heberden, 1931). His studies were 
confirmed and completed in 1837 by Schönlein (Schönlein JL, 1837) and in 1874 by Eduard 
Henoch (Henoch E, 1868). In 1862, Karl Von Rokitansky proposed that the origin of 
atherosclerosis is the result of the deposit of material that came from the blood, which 
subsequently induces arteritis or inflammation (Rokitansky K, 1852). He established that 
this inflammation started in the external layer or adventicia (Rokitansky K, 1852). The 
concept of vasculitis was consolidated after the pathological analysis by Rudolf Maier and 
Adolf Kussmaul (Kussmaul A, 1866). This was the first description and recognition of the 
polyarteritis nodosa. Around 1827, an association between purpura and abdominal pain 
was determined. The term Henoch-Schonlein purpura was given (Henoch E, 1868). 
It was in the XX century that Osler described a form of vasculitis that included purpura and 
visceral involvement (Glanzman E, 1920). This was later named Systemic Lupus 
Erythematosus (SLE). Wegener’s granulomatosis was described in 1931. But it was only 
until 1948 that Douglas Gaaidner proposed that Henoch-Scholein purpura (Klinge F, 1933), 
acute nephritis, rheumatic fever and polyarteritis nodosa had a common etiology and were 
associated to an antibody-antigen reaction that occurred at the blood vessel level. 
Subsequent descriptions of different cases of Wegener’s granulomatosis, Churg Strauss 
syndrome, Kawasaki, Henoch Schonlein, Behcet’s, RA, Takayasu’s, temporal arteritis and 
SLE were done (Wegener F, 1990; Hunder GG et al, 1990).  
The first descriptions of DIL were recorded in 1945 with the use of sulfadiazine (Hoffman 
BJ, 1945); and in 1953 with hydralazine (Alarcon Segovia D, 1967; Ullman S et al, 1974; Yung 
& Richardson, 1994). The presentation was similar to the one of Systemic Lupus 
Erythematosus: fever, arthritis, myalgias, and serositis with involvement of the pericardium 
and pleura (Yung & Richardson, 1994). 
In 1970, it was determined that DIV and DIL were usually observed in people with HLA 
DR0301 (Mielke et al, 1993; Gunnarsson I, 2000). 
It was in 1973 when it was established that immunosuppressive therapy improved the 
prognosis of patients with Wegener’s granulomatosis (Fauci & Wolff, 1993). 
Around 1990, the classification criterion of different vasculitis was established, as well as its 
therapeutic and diagnostic approach (Churg J, 1991). However, it was in 1994 when simple 
nomenclature was made. This classified the vasculitis in big vessel vasculitis (giant cell 
arteritis and Takayasu's); median vessel vasculitis (Polyarteritis nodosa); and small vessel 
vasculitis (Wegener’s granulomatosis, Churg Strauss syndrome, microscopic Poliangeítis, 
Henoch Schonlein purpura, Vasculitis induced by Cryoglobulins) (Jannette et al, 1994). 
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Vessel size  Presence of Granuloma.  No Granuloma 
Large Temporal arteritis.  Polyarteritis Nodosa. 
 Takayasu’s arteritis.  
Medium   Kawasaki’s disease 
 
Small Wegener’s Granulomatosis  Microscopic Polyangitis 
 Churg Strauss Syndrome  Henoch Schonlein purpura 
  Cutaneous leukocytolastic 
Table 1. Classification of vasculitis depending on the presence or not of granulomas, by 
Jennette et al 1994 
4. Clinical presentation  
Clinical manifestations vary as well as the organs affected. In general, it depends on the 
cause, localization, the size of the vessel affected, and the degree of ischemia. Symptoms 
commonly found are: purpura, erythema, urticaria, vesiculobullous lesions, superficial 
ulcers, splinter hemorrhages, scleritis, episcleritis, uveitis, neutrophilic granulomatous 
dermatitis, glomerulonephritis, gastric colic, pulmonary hemorrhage, constitutional 
symptoms. When the compromise is in the middle of medium-caliber vessels, we find 
subcutaneous nodules, deep ulcers, livedo reticularis, digital gangrene, mononeuritis, 
aneurysms, and ischemic lesions (Iglesias Gamarra A, et al, 2006).  
As we have stated, the most common skin manifestations are: Urticaria, edema, petequias, 
exanthema, livedo reticularis, purpura, vesicles or ulcerations. The distribution varies, 
affecting the extremities, trunk or both (Iglesias Gamarra A, et al, 2006). 
If there is damage of the muscular vessels, a myopathy may develop with myalgia, 
weakness and elevation of CK and LDH (Iglesias Gamarra A, et al, 2006). 
It is common to see a prodromal presentation of non specific symptoms like general malaise, 
weight loss, fever and night sweats. Specific symptoms develop once a major organ is 
affected. For example, in Wegener’s granulomatosis, there is compromise of the upper and 
lower airways and the kidneys. Similarly, the kidneys are affected in microscopic 
polyangitis. This results in hematuria, proteinuria and kidney failure. The lower airways 
affection may result in pulmonary hemorrhage, which is fatal if not recognized and treated 
in a timely manner (Iglesias Gamarra A, et al, 2006). 
In Churg Strauss the clinical presentation is often mistaken as asthma exacerbations. Chest x 
rays show transitory pulmonary infiltrates, and eosinophils are very elevated in blood. 
There might appear concomitant cutaneous vasculitis, as well as gastrointestinal 
abnormalities with abdominal pain and symptoms that can be confused with irritable bowel 
syndrome (Iglesias Gamarra A. et al, 2006). 
Polyarteritis nodosa is less frequent, but more severe and devastating. It causes ischemic 
infarcts of various organs, which can induce to hemorrhage, specially the in bowel, pancreas 
and gallbladder. Urinary tract compromise is seen in 50% of the patients, but it is 
uncommon to have severe kidney insufficiency (Jennette JC, 1994). 
In general, the gold standard diagnostic test for vasculitis is tissue biopsy that demonstrates 
fibrinoid necrosis with vascular inflammation. Common sources are the nose, lungs, skin or 
kidneys. Serological tests are also important in helping define the type of vasculitis (Iglesias 
Gamarra A, et al, 2006; Jennette JC, 1994). 
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In drug induced vasculitis, small vessels are usually affected. The histopathological findings 
are similar to other types of vasculitis. And this is usually considered a diagnosis of 
exclusion. Non specific symptoms are present as described above, including fever, weight 
loss, arthralgias and myalgias. Skin changes are frequently seen, like purpuric lesions, 
vesicles and bullae, urticaria and splinter hemorrhages. More severe cases may present with 
glomerulonephritis, alveolar hemorrhage, uveitis and scleritis. The syndrome might resolve 
in weeks after the drug has been discontinued. However in rare cases it might become 
persistent, especially in those with ANCA positive. There are no specific laboratory findings, 
eosinophilia is present in 79% of cases, ESR and CRP are commonly elevated. Hence, biopsy 
is mandatory (Jennette JC, 1994). 
5. Laboratory findings 
1. Complete blood counts and erythrosedimentation rate: Anemia is a common finding, 
usually normocytic, normochromic. Platelets are usually elevated, as is ESR. White 
blood cell counts are of extreme importance, since leucopenia is usually the limiting 
factor with immunosupression. 
2. Chemistries: To assess renal (BUN, creatinine, eGFR), hepatic (Liver function tests) and 
muscular (CK, aldolase, LDH) compromise. 
3. Creatinine is used to evaluate kidney function. An urianalysis is required to diagnose 
glomerular involvement, in which case proteinuria and hematuria are found. Kidney 
function is also a prognosis factor.  
4. Chest X rays, to look for lung involvement or pulmonary nodules. 
5. Electromyography (EMG) to assess nuropathy and neuritis. 
6. ANCA: Anti PR3 and anti MPO are present in 90% of the Wegener’s granulomatosis. 
7. Cryoglobulins and complement levels (C3 and C4). 
8. Hepatitis B, and C, which might be the underlying cause of cryoglobulins. 
9. Angiograms to evaluate vascular compromise in Takayasu’s artritis. 
6. Histopathology  
There is an inflammatory response, manifested as a cellular infiltration with subsequent 
wall vessel damage. Inflammation results in leukocytosis, and may end in vascular necrosis. 
When the latter occurs and becomes chronic, granulomas are usually present. 
Fibrinoid necrosis is characterized by replacement of the vascular wall by eosinophils, 
fibrinogen deposits, immunoglobulins. In general, there is leucocyte destruction, but 
lynfocites might also be affected.  
This results in immunoproliferative vasculitis. All the above findings make biopsy 
necessary. The skin, respiratory tract (either superior or inferior) and kidneys are the most 
frequently biopsied. Approximately 20% of cases of cutaneous vasculitis represent an 
adverse drug eruption and most will represent so-called hypersensitivity vasculitis (CLA) 
and exhibit a superficial dermal, small-vessel neutrophilic vasculitis or lymphocytic 
vasculitis (Carlson & Chen, 2006; Carlson & Chen, 2007). Identification of tissue eosinophilia 
in these biopsies is a clue to a drug etiology (Bahrami S, 2006). Pharmacological classes 
involved in drug-induced vasculitis are: 1. an ANCA-associated group, such as 
propylthiouracil, hydralazine, allopurinol, minocycline, penicillamine, and phenytoin; 2. an 
ANCA-negative group, such as colony-stimulating factors, isotretinoin, and methotrexate 
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(Holder SM et al, 2002). Identifying the offending drug is the most important aspect of 
treatment as its discontinuation is followed by a rapid improvement in the vasculitis in 
many cases.  
7. Small vessel vasculitis  
Small vessel vasculitis comprises a heterogeneous group of diseases and syndromes. To 
facilitate its understanding, they are classified as follows: 
1. Immune complex mediated: 
1.1 GoodPasture’s. 
1.2 Leucocitoclastic angitis. 
1.3 Henoch Schonlein Purpura. 
1.4 Urticarial Crioglobulinemia. 
2. ANCA associated vasculitis: 
2.1 Wegener’s granulomatosis. 
2.2 Microscopic polyangitis. 
2.3 Churg Strauss. 
2.4 Kidney vasculitis. 
2.5 Secondary vasculitis. 
3. Miscelaneous: 
3.1. Connective tissue disorders (Rheumatoid vasculitis, SLE, Sjogren and 
inflammatory myopathies). 
3.2 Paraneoplastic syndromes. 
3.3 Infections. 
3.4 Drug induced. 
8. Drug induced vasculitis mechanism  
As stated above, the mechanism with which a medication can induce a vasculitis varies, and 
different ones have been established. The presentation of the disease also differs depending 
not only on the type, but also on genetic factors, geographic regions, age, sex, and race.  
Clinically it is difficult to differentiate between drug induced and small vessel vasculitis. 
Skin manifestations are the most common in DIV, which ranges from a maculopapular rash 
to a palpable purpura. There might be concomitant arthralgias, arhthritis, kidney and liver 
compromise, as well as central nervous system affection (Molina J et al ,2000). 
The duration of the process is also variable. It may resolve in a few weeks after 
discontinuation of the culprit agent, or persist afterwards. This is especially true in ANCA 
positive cases. 
Again, DIV is a diagnosis of exclusion, and can only be made once other types of vasculitis, 
infections and malignancy have been ruled out (Jennette & Falk, 1997). There is no 
diagnostic test available. Eosinophilia is present in 79% of the cases (Jennette & Falk, 1997; 
Calabrese LH et al, 1990). A biopsy is usually required, and the list of medications taken in 
the last 6 months reviewed. 
Treatment includes the discontinuation of the medication and immunosuppressive agents. 
Patients with idiopathic vasculitis, more commonly develop ANCA to one neutrophil 
antigen, whereas in DIV it is usual to find several (Calabrese LH et al, 1990, Savige J et al 
2000). 
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When used, anti-TNF agents can induce DIV. Cases have been described of antibodies 
against double stranded DNA when infliximab is used (Buttman et al, 2005). 
Procainamide and Hydralazine share a structure similar to the nucleosome, which can 
induce an immunogenic reaction. This results in the formation of antibodies similar to the 
ones found in SLE. These drugs can also cause a direct toxicity by its metabolics, which 
inhibit DNA methyltransferase and induces autoimmunity (Carlson et al, 2005). 
Interferon is a naturally found protein in the human immune system. There are three known 
types: alpha, gamma and lambda. The production of interferon is induced by interleukins 
and TNF. Different types of cells produce interferon: T and B cells, macrophages, fibroblasts, 
endothelial cells and osteoblasts. They constitute and important mechanism of defense 
against viruses, stimulating macrophages and natural killer cells. In synthesis, interferon 
prevents the viral replication and induces the destruction of infected cells. It was in the 80’s 
when using DNA recombinant technology that interferon was produced massively. This is 
commonly used in the treatment of certain cancers, hepatitis C and B, as well of multiple 
sclerosis among others. It is given as an intramuscular injection. Frequent adverse reactions 
include: flu like symptoms, fever, myalgia, general malaise, headaches, and rarely seizures. 
Depression is also observed (Wiik, A 2008; O’Sullivan et al 2006). Most of the side effects are 
reversible, once treatment is completed (O’Sullivan et al 2006, Coppola G, 2006). 
Autoimmune side effects are rare. The induction of antithyroglobulins, sarcoidosis, diabetes 
and arthritis has been described. Buttmann proposed three possible mechanisms (Coppola 
G, 2006, Buttmann et al, 2005): 
1. Quimiotactic effect of the immune system cells. 
2. Direct effect over immune cells. 
3. Indirect effect over immune cells through induction of proinflammatory substances. 
9. Therapeutic approach 
The conventional treatment of systemic vasculitis was introduced by Wolfe and Fauci in the 
1970’s with the use of cyclophosphamide and steroids (Fauci & Wolff, 1973). This consists of 
a year of induction with cyclophosphamide and 4 weeks of pulse dose steroids. After the 
initial 4 weeks, the steroids are gradually tapered. However, the toxicity of oral 
cyclophosphamide is high, with a mortality rate ranging from 14 – 20%. Common side 
effects are Myelodisplastic syndromes (8%), Neoplasia (4.5%), severe infections (26%) 
(Hogan SL, 2005; Koldingsnes & Nossent H, 2002; Mukhtyar C, 2009). 
Due to the above, new strategies have been proposed with the purpose of reducing the 
overall accumulation. Currently, the parenteral approach is more commonly used with a 
dose of 0.6 mg/m2 (Reinhold-Keller et al, 2000). 
Mycophenolate mofetil (MMF) is an alternative. It is an immunosuppressive agent; inosine 
monophosphate dehydrogenase (IMPDH) 23 inhibitor (Huang Y, 2005). MMF is rapidly 
absorbed following oral administration and hydrolyzed to form MPA, which is the active 
metabolite. MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine 
monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of 
guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-
lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, 
whereas other cell types can utilize salvage pathways, MPA has potent cytostatic effects on 
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lymphocytes. MPA inhibits proliferative responses of T- and B-lymphocytes to both 
mitogenic and allospecific stimulation. The addition of guanosine or deoxyguanosine 
reverses the cytostatic effects of MPA on lymphocytes. MPA also suppresses antibody 
formation by B-lymphocytes. MPA prevents the glycosylation of lymphocyte and monocyte 
glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit 
recruitment of leukocytes into sites of inflammation. Once remission is achieved, 
maintaining it is a challenge (Joy M et al, 2005; Stassen P, 2005). The ultimate goal is to 
minimize the toxicity. 
In drug induced vasculitis, the first step is the discontinuation of the medication. If there is 
potentially fatal compromise, steroids and cyclophosphamide should be given. Different 
approaches have been described. In the first one, cyclophosphomide is administered in 
monthly boluses for 6 months, then every 3 months for 2 years. The alternative is to give the 
monthly boluses for 6 months, and then use azathioprine daily for 2 years (Klemmer PJ et al, 
2003). Methorexate might be used for maintenance, too. 
10. Case presentation 
We had the case of a 42 year old woman with a history of multiple sclerosis (MS) diagnosed 
9 years ago. Three years after the diagnosis was established, she was initiated on Beta 
Interferon 1a. Two years later, she developed non pruritic, palpable purpura in her lower 
extremities with subsequent ulceration and edema. Biopsy was consistent with vasculitis 
(Daza JS, 2008). She was then treated with high dose steroids, with poor response, and then 
started on cyclophosphamide. Beta interferon was discontinued. Resolution of the lesions 
was obtained. 
 
 
 
 
 
 
 
Fig. 1. MRI flash fair image: hyperdense lesions in the yuxtacortical area bilaterally, as well 
as in the semioval centre and periventricular matter. 
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Fig. 2. and 3. In our clinical case lesions are seen in different stages of evolution, some 
necrotic and scarred other areas hyper pigmentation at the ankle and dorsum of the foot that 
correspond to areas of vasculitis 
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Fig. 4. Skin with preserved epidermis. Superficial and medial dermis with minimal edema. 
Small vessels with prominent endothelial cells; some of them obstructing the lumen. The 
wall vessels appears with fibrinoid exudates, neutrophils and debris. Above findings are 
compatible with small vessel vasculitis of the lower extremities. 
The frequency of MS and vasculitis together is exceptional. This was first published in 1998. 
It has been hypothesized that these reactions are related to the presence of antibodies 
against interferon beta, which usually increase during the appearance of the lesions, and 
decrease with their resolution (Szilasiová J, 2003; Daza JS, 2008). 
11. Conclusion 
Vasculitis is a group of diseases characterized by vascular inflammation, which results in 
decrease of blood flow, and blood vessel wall damage. Any vessel may be affected, as well 
as one or several organs. 
In drug induced vasculitis, small vessels are usually affected. Again this is a diagnosis of 
exclusion. The diagnosis is a clinical one, with the support of serologic and histological 
findings. The clinical manifestations are similar to the other vasculitis. The skin, 
subcutaneous tissue, kidneys and lungs are most commonly affected. C-ANCA antibodies 
are usually positive. Interferon is a protein naturally produced by the immune system as a 
response to viruses or malignant cells. Interferon beta is a biological product obtained by 
DNA recombination techniques, and is used for treatment of MS. Immune complications 
with this therapy are rare. 
In the article, a patient treated for multiple sclerosis with interferon was presented. She 
developed vasculitis, which was later determined to be caused by Interferon, and was 
treated accordingly with the scheme depicted above. 
The use of any medication opens the possibility to complications and reactions. It is the role 
of the physician to determine when the benefits outweigh the risks, and once the treatment 
has been established, close follow up is required. 
Drug induced vasculitis, although rare, are not exceptional and should be included in the 
differential diagnosis of any vasculitis.  
Research is needed, to learn which patients have higher possibilities to develop drug 
induced vasculitis, so screening methods can be designed to avoid such medications in 
susceptible individuals. 
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